Clinical Therapeutics

Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis
pp. 177-192(16)
Authors: Ballantyne C.M.; Pazzucconi F.; Pinto X.; Reckless J.P.; Stein E.; McKenney J.; Bortolini M.; Tong Chiang Y.

Cefprozil versus high-dose amoxicillin/clavulanate in children with acute otitis media
pp. 193-204(12)
Authors: Hedrick J.A.; Sher L.D.; Schwartz R.H.; Pierce P.

Comparison of the cumulative irritation potential of adapalene gel and cream with that of erythromycin/tretinoin solution and gel and erythromycin/isotretinoin gel
pp. 205-212(8)
Authors: Queille-Roussel C.; Poncet M.; Mesaros S.; Clucas A.; Baker M.; Soloff A.-M.

Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee
pp. 213-227(15)
Authors: Williams G.W.; Hubbard R.C.; Yu S.S.; Zhao W.; Steven Geis G.

Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults
pp. 228-241(14)
Authors: Gimbel J.S.; Brugger A.; Zhao W.; Verburg K.M.; Geis G.S.

Effects of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine
pp. 242-251(10)
Authors: Fuseau E.; Petricoul O.; Sabin A.; Pereira A.; O'Quinn S.; Thein S.; Leibowitz M.; Purdon H.; McNeal S.; Salonen R.; Metz A.; Coates P.

Safety profile and tolerability of amprenavir in patients enrolled in an early access program
pp. 252-259(8)
Authors: Scott T.; Garris C.; Rogers M.; Graham N.; Garrett L.; Pedneault L.

Efficacy, tolerability, and patient satisfaction with 50- and 100-mg sumatriptan tablets in those initially dissatisfied with the efficacy of 50-mg sumatriptan tablets
pp. 260-271(12)
Authors: Savani N.; Pfaffenrath V.; Rice L.; Boswell D.; Black L.; Jones M.; Sumatriptan SUMB4007 Study Group

Pharmacogenomics: here it comes, ready or not
pp. 274-275(2)
Author: Coons S.J.

Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease
pp. 276-283(8)
Authors: Attanasio E.; Russo P.; Allen S.E.

Economic implications of early treatment of migraine with sumatriptan tablets
pp. 284-291(8)
Authors: Cady R.K.; Sheftell F.; Lipton R.B.; Kwong W.J.; O'Quinn S.

Using forecasting models to estimate the effects of changes in the composition of claims for selective serotonin reuptake inhibitors on expenditures
pp. 292-306(15)
Authors: Dewa C.S.; Hoch J.S.; Goering P.

Dear Dr. Walson:
pp. 307-307(1)
Authors: Glazer N.B.; Cheatham W.W.

Drs. Malinowski and Bolesta reply:
pp. 308-308(1)
Authors: Malinowski J.M.; Bolesta S.

Rosiglitazone in the Treatment of Type 2 Diabetes Mellitus: A Critical Review - by J. Malinowski and S. Bolesta, which appeared in the October 2000 issue, contained an error. Table VI indicates that pioglitazone treatment increases triglyceride levels by 9.0to 9.6, when in fact pioglitazone has been shown to decrease triglyceride levels by that percentage.
pp. 309-309(1)